Hologic price target raised to $95 from $80 at Raymond James

Raymond James analyst Andrew Cooper raised the firm’s price target on Hologic to $95 from $80 and keeps an Outperform rating on the shares. The full release of Q1 numbers built on the preannouncement last month by surpassing at least EPS expectations and continuing to call for strength across segments, the analyst tells investors in a research note. While the firm is "encouraged" by the tone and operating margin dynamics, the guidance increase is "relatively uninspiring" vs. the magnitude of the Q1 beat, Raymond James says.